The MoU concerns all assets associated with Simris’ production facility for microalgae in Hammenhög. The parties have agreed on an indicative valuation principle whereby the purchase price is expected to be in line with the book value of the assets, subject to satisfactory completion of legal, technical and operational due diligence, as well as the negotiation and execution of a definitive asset purchase agreement.

Under the MoU, Immunrise intends to conduct due diligence with the objective of submitting a firm and binding offer no later than 1 March 2026. Subject to the outcome of the process, the parties aim to enter into a definitive agreement by 31 March 2026.

The MoU includes customary provisions on exclusivity and confidentiality, which are binding on the parties. Apart from these provisions, the MoU does not constitute a binding commitment to complete the transaction. There can be no assurance that a definitive agreement will be entered into or that the transaction will be completed.

The Board of Directors of Simris considers the potential transaction to be aligned with the Company’s strategic priorities and, if completed, to have the potential to strengthen the Company’s financial position and strategic focus.

Further information will be communicated as the process progresses.